168 related articles for article (PubMed ID: 33927695)
1. Characteristics, Treatment, Outcomes, and Survival in Neuroendocrine G1 and G2 Pancreatic Tumors: Experiences From a Single Tertiary Referral Center.
Calissendorff J; Bjellerup-Calissendorff F; Bränström R; Juhlin CC; Falhammar H
Front Endocrinol (Lausanne); 2021; 12():657698. PubMed ID: 33927695
[TBL] [Abstract][Full Text] [Related]
2. Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.
Genç CG; Falconi M; Partelli S; Muffatti F; van Eeden S; Doglioni C; Klümpen HJ; van Eijck CHJ; Nieveen van Dijkum EJM
Ann Surg Oncol; 2018 Aug; 25(8):2467-2474. PubMed ID: 29789972
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
4. Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease.
Miller HC; Drymousis P; Flora R; Goldin R; Spalding D; Frilling A
World J Surg; 2014 Jun; 38(6):1353-61. PubMed ID: 24493070
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors.
Özaslan E; Demir S; Karaca H; Güven K
Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):836-41. PubMed ID: 26945127
[TBL] [Abstract][Full Text] [Related]
6. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
7. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations.
Russolillo N; Vigano' L; Razzore P; Langella S; Motta M; Bertuzzo F; Papotti M; Ferrero A
Eur J Surg Oncol; 2015 Jun; 41(6):751-7. PubMed ID: 25887286
[TBL] [Abstract][Full Text] [Related]
8. Ki-67 cytological index can distinguish well-differentiated from poorly differentiated pancreatic neuroendocrine tumors: a comparative cytohistological study of 53 cases.
Carlinfante G; Baccarini P; Berretti D; Cassetti T; Cavina M; Conigliaro R; De Pellegrin A; Di Tommaso L; Fabbri C; Fornelli A; Frasoldati A; Gardini G; Losi L; Maccio L; Manta R; Pagano N; Sassatelli R; Serra S; Camellini L
Virchows Arch; 2014 Jul; 465(1):49-55. PubMed ID: 24807732
[TBL] [Abstract][Full Text] [Related]
9. Fine-needle aspiration biopsy of pancreatic neuroendocrine tumors: Correlation between Ki-67 index in cytological samples and clinical behavior.
Díaz Del Arco C; Esteban López-Jamar JM; Ortega Medina L; Díaz Pérez JÁ; Fernández Aceñero MJ
Diagn Cytopathol; 2017 Jan; 45(1):29-35. PubMed ID: 27863178
[TBL] [Abstract][Full Text] [Related]
10. ASO Author Reflections: Pancreatic Neuroendocrine Tumor Recurrence and Survival Predicted by Ki67.
Nieveen van Dijkum EJM
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):531-532. PubMed ID: 30519760
[No Abstract] [Full Text] [Related]
11. Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival.
Keck KJ; Choi A; Maxwell JE; Li G; O'Dorisio TM; Breheny P; Bellizzi AM; Howe JR
Ann Surg Oncol; 2017 Aug; 24(8):2206-2212. PubMed ID: 28560597
[TBL] [Abstract][Full Text] [Related]
12. Survival Analyses for Patients With Surgically Resected Pancreatic Neuroendocrine Tumors by World Health Organization 2010 Grading Classifications and American Joint Committee on Cancer 2010 Staging Systems.
Yang M; Ke NW; Zhang Y; Zeng L; Tan CL; Zhang H; Mai G; Tian BL; Liu XB
Medicine (Baltimore); 2015 Dec; 94(48):e2156. PubMed ID: 26632896
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine tumors of the pancreas: a retrospective single-center analysis using the ENETS TNM-classification and immunohistochemical markers for risk stratification.
Brunner SM; Weber F; Werner JM; Agha A; Farkas SA; Schlitt HJ; Hornung M
BMC Surg; 2015 Apr; 15():49. PubMed ID: 25928025
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.
Deng BY; Liu F; Yin SN; Chen AP; Xu L; Li B
Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):261-268. PubMed ID: 29307515
[TBL] [Abstract][Full Text] [Related]
15. The conundrum of < 2-cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management.
Lopez-Aguiar AG; Ethun CG; Zaidi MY; Rocha FG; Poultsides GA; Dillhoff M; Fields RC; Idrees K; Cho CS; Abbott DE; Cardona K; Maithel SK
Surgery; 2019 Jul; 166(1):15-21. PubMed ID: 31072670
[TBL] [Abstract][Full Text] [Related]
16. The size of well differentiated pancreatic neuroendocrine tumors correlates with Ki67 proliferative index and is not associated with age.
Partelli S; Muffatti F; Rancoita PMV; Andreasi V; Balzano G; Crippa S; Doglioni C; Rubini C; Zamboni G; Falconi M
Dig Liver Dis; 2019 May; 51(5):735-740. PubMed ID: 30723019
[TBL] [Abstract][Full Text] [Related]
17. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for short recurrence-free survival after resection of pancreatic neuroendocrine tumor (PanNET) liver metastases: which patients should undergo resection?
Masui T; Nagai K; Anazawa T; Kasai Y; Sato A; Nakano K; Uchida Y; Yogo A; Kawaguchi Y; Takaori K; Uemoto S
Scand J Gastroenterol; 2020 Apr; 55(4):479-484. PubMed ID: 32223573
[No Abstract] [Full Text] [Related]
19. The Ki-67 labeling index and lymphatic/venous permeation predict the metastatic potential of rectal neuroendocrine tumors.
Sugimoto S; Hotta K; Shimoda T; Imai K; Yamaguchi Y; Nakajima T; Oishi T; Mori K; Takizawa K; Kakushima N; Tanaka M; Kawata N; Matsubayashi H; Ono H
Surg Endosc; 2016 Oct; 30(10):4239-48. PubMed ID: 26718357
[TBL] [Abstract][Full Text] [Related]
20. Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study.
Larghi A; Capurso G; Carnuccio A; Ricci R; Alfieri S; Galasso D; Lugli F; Bianchi A; Panzuto F; De Marinis L; Falconi M; Delle Fave G; Doglietto GB; Costamagna G; Rindi G
Gastrointest Endosc; 2012 Sep; 76(3):570-7. PubMed ID: 22898415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]